Screener
AOCI at other companies
Other financials
Where this comes from
Reported directly by ImmunityBio, Inc. in its filing.
Tagged under the XBRL concept us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax.
The source filing: ImmunityBio, Inc.’s 10-Q, filed May 7, 2026.
- Filed
- May 7, 2026, 7:37 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001326110-26-000059
| Line item | March 31, 2026 | December 31, 2025 |
|---|---|---|
| Common Stock, $0.0001 par value; 1,650,000,000 shares authorized as of March 31, 2026 and December 31, 2025; 1,047,341,146 and 1,011,800,008 shares issued and outstanding as of March 31, 2026 and December 31, 2025, respectively; excluding treasury stock, 163,800 shares outstanding as of March 31, 2026 and December 31, 2025 | $104 | $101 |
| Additional paid-in capital | 3,461,865 | 3,197,120 |
| Accumulated deficit | (4,359,428) | (3,726,646) |
| Accumulated other comprehensive income | 27,453 | 28,956 |
| Total ImmunityBio stockholders’ deficit | (870,006) | (500,469) |
| Noncontrolling interests | 880 | 895 |
| Total stockholders’ deficit | (869,126) | (499,574) |
| Total liabilities and stockholders’ deficit | $646,637 | $501,898 |
ITEM 1. FINANCIAL STATEMENTS.
FAQ
- What is ImmunityBio, Inc.'s AOCI?
- ImmunityBio, Inc. (IBRX) reported AOCI of $27.45M in Q1 2026.
- How has ImmunityBio, Inc.'s AOCI changed year-over-year?
- ImmunityBio, Inc.'s AOCI increased by 37.6% year-over-year, from $19.96M to $27.45M.
- What is the long-term trend for ImmunityBio, Inc.'s AOCI?
- Over 5 years (2020 to 2025), ImmunityBio, Inc.'s AOCI has grown at a 198.6% compound annual growth rate (CAGR), from $122K to $28.96M.
- What does AOCI mean?
- Accumulated gains and losses bypassing the income statement — unrealized investment gains/losses, currency translation, pension adjustments, and hedge results.
Ask your AI about ImmunityBio, Inc.'s aoci.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude